Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)

BACKGROUND: The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non–small cell lung cancer; however, it is unclear whether the same is applicable for small cell lung cancer (SCLC). We evaluated the efficacy of second‐lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Uematsu, Shinya, Kitazono, Satoru, Tanaka, Hisashi, Saito, Ryota, Kawashima, Yosuke, Ohyanagi, Fumiyoshi, Tozuka, Takehiro, Ryosuke, Tsugitomi, Sakatani, Toshio, Horiike, Atsushi, Yoshizawa, Takahiro, Saiki, Masafumi, Tambo, Yuichi, Koyama, Junji, Kanazu, Masaki, Kudo, Keita, Tsuchiya‐Kawano, Yuko, Yanagitani, Noriko, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834695/
https://www.ncbi.nlm.nih.gov/pubmed/36408699
http://dx.doi.org/10.1111/1759-7714.14729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834695/
https://www.ncbi.nlm.nih.gov/pubmed/36408699
http://dx.doi.org/10.1111/1759-7714.14729

Ejemplares similares